89.3%
BASECAMP-1BASECAMP-1advanced solid malignancylogic-gated Tmod chimeric antigen receptor T-cell therapiesA2 BiotherapeuticsTempus AIadvanced solid malignancies
…1918 patients at 13 study sites were consented and screened for BASECAMP-1; of these, 30 patients with tumour-associated HLA-A*02 LOH were…